NEW YORK--(BUSINESS WIRE)--Lev Pharmaceuticals, Inc. (OTCBB:LEVP.OB) announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) related to its biologics license application (BLA) for Cinryze™ (C1 inhibitor) for both the acute and prophylactic treatment of hereditary angioedema (HAE), or C1 inhibitor deficiency.
